SCHEMBL939870

SCHEMBL939870

CCCNC1CCC(=O)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 11/20 0.42
DRD2 P14416 11/20 0.42
DRD4 P21917 5/20 0.42
HTR1B P28222 3/20 0.42
HTR1D P28221 3/20 0.42
HRH2 P25021 2/20 0.41
ADRA2A P08913 2/20 0.41
ADRB2 P07550 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
HTR2A P28223 1/20 0.41
HTR7 P34969 1/20 0.41
ADRA1A P35348 1/20 0.41
HRH1 P35367 1/20 0.41
HTR2B P41595 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
HRH4 Q9H3N8 1/20 0.41
GNAI3 P08754 1/20 0.36
GNAO1 P09471 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene SCHEMBL977547 0.96 DRD3 (0.41) DRD3DRD2DRD4HTR1BHTR1D
SCHEMBL21047707 0.88 GNAI3 (0.46) DRD3DRD2SIGMAR1GNAI3GNAO1
SCHEMBL11294055 0.86 GNAI3 (0.53) DRD3DRD2GNAI3GNAO1GNAI1
SCHEMBL21047880 0.84 GNAI3 (0.56) DRD3DRD2GNAI3GNAO1GNAI1
SCHEMBL21047578 0.84 GNAI3 (0.56) DRD3DRD2GNAI3GNAO1GNAI1
SCHEMBL21047754 0.84 GNAI3 (0.56) DRD3DRD2GNAI3GNAO1GNAI1
SCHEMBL21047738 0.84 GNAI3 (0.56) DRD3DRD2GNAI3GNAO1GNAI1
SCHEMBL21047868 0.84 GNAI3 (0.56) DRD3DRD2GNAI3GNAO1GNAI1
SCHEMBL11014162 0.84 GNAI3 (0.56) DRD3DRD2GNAI3GNAO1GNAI1
SCHEMBL11004775 0.84 GNAI3 (0.56) DRD3DRD2GNAI3GNAO1GNAI1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868029-B2 Process for the preparation of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles from cyclohexanes and cyclohexanones as intermediates GENERICS [UK] LIMITED (GB) 2011-01-11 US claimed
EP-1542981-B1 PROCESS FOR THE PREPARATION OF 2-AMINO-4,5,6,7-TETRAHYDRO-6-AMINOBENZOTHIAZOLES FROM CYCLOHEXANES AND CYCLOHEXANONES AS INTERMEDIATES GENERICS UK LTD (GB) 2009-07-22 EP claimed
WO-2005100020-A2 PRIMER-LESS ABRASION COATING FOR ORGANIC GLASS ARTICLES VISION-EASE LENS (US) 2005-10-27 WO claimed
US-20050238882-A1 Primer-less abrasion coating for organic glass articles VISION-EASE LENS 2005-10-27 US claimed
EP-3495341-B1 PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL KANTO DENKA KOGYO KK (JP) 2022-11-02 EP disclosed
CN-109563016-B Method for producing perfluoroalkyl compound using monohydroperfluoroalkane as starting material 关东电化工业株式会社 2022-05-13 CN disclosed
US-10450253-B2 Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material KANTO DENKA KOGYO CO., LTD. (JP) 2019-10-22 US disclosed
EP-3495341-A1 METHOD FOR PRODUCING PERFLUOROALKYL COMPOUND USING MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL Kanto Denka Kogyo Co., Ltd. (JP) 2019-06-12 EP disclosed
US-20190169107-A1 PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) 2019-06-06 US disclosed
EP-1884514-B1 METHOD FOR THE RESOLUTION OF 2-AMINO-6-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOL AND INTERMEDIATE COMPOUNDS CRYSTAL PHARMA SAU (ES) 2017-04-12 EP disclosed
EP-1884514-B1 METHOD FOR THE RESOLUTION OF 2-AMINO-6-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOL AND INTERMEDIATE COMPOUNDS CRYSTAL PHARMA SAU (ES) 2017-04-12 EP disclosed
US-8952173-B2 Method for the resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazol and intermediate compounds CRYSTAL PHARMA, S.A.U. (ES) 2015-02-10 US disclosed
WO-2005100020-A2 PRIMER-LESS ABRASION COATING FOR ORGANIC GLASS ARTICLES VISION-EASE LENS (US) 2005-10-27 WO disclosed
US-20050238882-A1 Primer-less abrasion coating for organic glass articles VISION-EASE LENS 2005-10-27 US disclosed
EP-1542981-A1 PROCESS FOR THE PREPARATION OF 2-AMINO-4,5,6,7-TETRAHYDRO-6-AMINOBENZOTHIAOLES FROM CYCLOHEXANES AND CYCLOHEXANONES AS INTERMEDIATES Generics (UK) Limited (GB) 2005-06-22 EP disclosed
WO-2004026850-A1 PROCESS FOR THE PREPARATION OF 2-AMINO-4,5,6,7-TETRAHYDRO-6-AMINOBENZOTHIAOLES FROM CYCLOHEXANES AND CYCLOHEXANONES AS INTERMEDIATES GENERICS [UK] LIMITED (GB) 2004-04-01 WO disclosed
US-4886812-A REGULATING DOPAMINE CONCENTRATION; PARKINSON DISEASE, HYPOTENSIVE AGENT, SCHIZOPHRENIA DR. KARL THOMAE GMBH (DE) 1989-12-12 US disclosed
US-4843086-A HYPOTENSIVE AGENTS, SCHIZOPHRENIA, PARKINSON'S DISEASE BOEHRINGER INGELHEIM KG (DE) 1989-06-27 US disclosed
US-4731374-A PARKINSON*S DISEASE DR. KARL THOMAE GMBH (DE) 1988-03-15 US disclosed
EP-0186087-A1 Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs Dr. Karl Thomae GmbH (DE) 1986-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190169107-A1 PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL PFKFB1, PFKFB4, PFAS DRD3 3582/4885DRD2 3499/4885DRD4 2367/4885
US-10450253-B2 Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material PFKFB1, PFKFB4, PFAS DRD3 3582/4885DRD2 3499/4885DRD4 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.